respons
sarscov
infect
neutral
antibodi
gener
spike
protein
determin
activ
region
allow
viral
escap
neutral
would
enabl
use
antibodi
futur
passiv
immunotherapi
immun
mice
uvinactiv
sarscov
gener
three
anti
monoclon
antibodi
establish
sever
neutral
escap
mutant
protein
identifi
sever
amino
acid
substitut
includ
domain
region
presenc
neutral
antibodi
doubl
mutant
substitut
domain
exhibit
greater
growth
advantag
one
substitut
importantli
combin
two
monoclon
antibodi
target
differ
epitop
effect
almost
complet
suppress
wild
type
viru
replic
thu
effect
passiv
immunotherapi
import
use
neutral
antibodi
recogn
region
sever
acut
respiratori
syndrom
sar
caus
novel
coronaviru
sarscov
emerg
seriou
epidem
late
earli
peopl
infect
nearli
die
coronavirus
envelop
positivestrand
rna
virus
encod
structur
spike
envelop
e
membran
nucleocapsid
n
protein
well
nonstructur
protein
amino
acid
aa
viral
protein
mediat
cell
attach
membran
fusion
domain
sarscov
defin
although
protein
sarscov
appear
cleav
viral
receptor
bind
domain
rbd
protein
locat
residu
domain
interact
angiotensinconvert
enzym
identifi
sarscov
receptor
although
sar
report
sinc
protect
vaccin
reliabl
diagnost
avail
control
outbreak
might
reemerg
convalesc
serum
report
contain
high
titer
igg
antibodi
sarscov
suggest
antisarscov
antibodi
could
use
passiv
immun
sar
among
differ
protein
candid
recogn
antisarscov
antibodi
protein
emerg
major
target
vaccin
develop
particular
rbd
contain
import
epitop
neutral
antibodi
although
neutral
mab
recogn
ntermin
region
aa
also
report
find
suggest
sarscov
infect
could
inhibit
interf
interact
specif
bind
rbd
domain
contain
put
fusion
peptid
two
heptad
repeat
region
associ
form
sixhelix
bundl
structur
human
immunodefici
viru
type
hiv
viru
neutral
monoclon
antibodi
mab
recogn
epitop
proxim
viral
membran
similarli
antibodi
target
membraneanchor
domain
region
abl
neutral
sarscov
furthermor
mani
neutral
epitop
map
region
identifi
antisera
convalesc
sar
patient
togeth
indic
sarscov
neutral
antibodi
target
either
domain
previous
report
high
level
anti
antin
antibodi
induc
mice
immun
uvinactiv
sarscov
gener
anti
mab
mice
demonstr
effici
neutral
sarscov
infect
vero
cell
determin
region
mab
biolog
import
neutral
select
neutralizationescap
mutant
clone
dominantli
grew
select
pressur
neutral
mab
determin
amino
acid
substitut
mutant
protein
analyz
level
viral
resist
confer
neutral
antibodi
vero
cell
atcc
grown
eagl
minim
essenti
medium
mem
nonessenti
amino
acid
invitrogen
carlsbad
ca
supplement
fb
japan
bioserum
mm
lglutamin
mm
sodium
pyruv
gl
sodium
bicarbon
antibiot
sarscov
kindli
provid
dr
jsm
peiri
depart
microbiolog
univers
hong
kong
virus
propag
assay
use
vero
cell
b
cell
express
sarscov
protein
maintain
supplement
fb
mm
lglutamin
mgml
blasticidin
invitrogen
antibiot
plaqu
titrat
approxim
pfu
sarscov
incub
serial
dilut
anti
mab
control
igg
h
c
ad
confluent
vero
cell
plate
duplic
h
incub
cell
overplay
low
melt
agaros
seaplaqu
fmc
corp
rockland
mem
supplement
fb
day
viru
inactiv
formalinpb
sampl
stain
formalin
pb
contain
crystal
violet
sigmaaldrich
number
plaqu
obtain
presenc
mab
calcul
percentag
rel
obtain
control
mous
igg
alon
larg
affect
plaqu
format
even
mgml
data
shown
vero
cell
spread
onto
labtek
chamber
slide
nalg
nunc
inc
napevil
il
either
infect
sarscov
moi
uninfect
cytopath
effect
cpe
observ
slide
wash
pb
fix
methanol
aceton
min
c
cell
permeabil
pb
contain
tween
treat
mab
follow
fitcconjug
antimous
igg
nuclei
stain
dapi
invitrogen
coverslip
mount
onto
slide
use
antifad
reagent
fluoromount
g
invitrogen
sampl
examin
confoc
microscop
carl
zeiss
co
ltd
cell
suspend
stain
buffer
pb
contain
fb
sodium
azid
contain
goat
serum
follow
incub
min
biotinyl
mab
mgml
three
wash
cell
incub
streptavidin
apc
ebio
inc
tokyo
japan
min
ice
wash
analyz
use
facscalibur
bd
bioscienc
san
jose
ca
antibodi
competit
assay
conduct
use
combin
unlabel
biotinyl
mab
elisapl
nunc
coat
uvinactiv
sarscov
mgml
mm
sodium
bicarbon
buffer
ph
c
overnight
block
pierc
room
temperatur
min
unlabel
antibodi
mgml
pbsetween
ad
sampl
incub
overnight
c
biotinyl
antibodi
ad
final
concentr
mgml
amount
bound
biotinyl
antibodi
quantit
streptavidineehrp
dilut
southernbiotech
use
ophenylenediamin
invitrogen
substrat
isol
escap
mutant
perform
previous
describ
brief
sarscov
incub
h
c
presenc
mgml
mgml
mgml
mab
concentr
estim
suboptim
concentr
plaqu
inhibit
base
neutral
activ
half
tissu
cultur
infecti
dose
tcid
viru
antibodi
incub
ad
confluent
vero
cell
plate
h
incub
cell
overplay
agar
nobl
gibco
ny
mem
contain
fb
mab
day
five
plaqu
sampl
form
presenc
mab
pick
togeth
support
agar
soak
ml
medium
potenti
escapemut
virus
obtain
three
round
plaqu
purif
first
plaqu
purif
escap
mutant
virus
obtain
presenc
design
respect
follow
subclon
number
virus
store
c
viral
rna
extract
plaquesoak
medium
use
qiaamp
viral
rna
mini
kit
qiagen
gmbh
germani
cdna
fragment
synthes
qiagen
onestep
rtpcr
kit
qiagen
use
primer
set
span
entir
gene
tabl
nucleotid
sequenc
determin
bigdy
termin
appli
biosystem
previous
establish
mous
mab
igg
subclass
sarscov
protein
mab
demonstr
neutral
activ
measur
predict
recogn
conform
epitop
protein
precis
determin
neutral
titer
first
perform
sarscov
plaqu
assay
shown
fig
inhibit
plaqu
format
complet
mgml
wherea
plaqu
inhibit
weaker
approxim
mgml
requir
achiev
similar
level
plaqu
inhibit
contrast
neutral
activ
concentr
less
mgml
least
mgml
requir
immunofluoresc
analysi
sarscovinfect
vero
cell
reveal
three
mab
react
strongli
cell
membran
well
perinuclear
ergolgi
rich
region
fig
character
mab
murin
cell
express
protein
stain
biotinyl
anti
mab
analyz
use
facscalibur
stain
surfac
cell
margin
wherea
stain
signal
obtain
stronger
fig
upper
panel
importantli
signal
substanti
enhanc
combin
fig
lower
panel
note
previous
show
express
cell
detect
high
level
use
mixtur
anti
mab
defin
epitop
target
mab
next
perform
competit
experi
shown
fig
bind
virion
inhibit
either
wherea
bind
partial
inhibit
also
togeth
indic
mab
recogn
two
distinct
epitop
protein
one
epitop
recogn
taken
togeth
anti
mab
like
recogn
distinct
conform
epitop
protein
sinc
viral
entri
cell
often
accompani
conform
chang
protein
vivo
impact
neutral
epitop
identifi
vitro
assay
need
evalu
importantli
deduc
amino
acid
substitut
escap
mutant
variou
neutral
antibodi
singl
amino
acid
implic
integr
antigen
site
ident
amino
acid
repres
import
inform
respect
tabl
primer
use
nucleotid
sequenc
spike
region
aeh
primer
also
use
cdna
synthesi
emerg
escap
mutant
virus
therefor
gener
sarscov
clone
resist
anti
mab
neutral
vero
cell
infect
wild
type
viru
presenc
suboptim
concentr
mab
rna
escap
mutant
resist
virus
extract
reversetranscrib
sequenc
deduc
amino
acid
substitut
mutant
clone
summar
tabl
detect
aspart
acid
asparagin
substitut
aa
domain
three
four
clone
escap
neutral
addit
identifi
tyrosin
phenylalanin
substitut
aa
rbd
clone
escap
neutral
chang
includ
valin
glycin
aa
domain
alanin
valin
aa
domain
escap
mutant
respect
thu
like
residu
play
import
role
interact
neutral
antibodi
sarscov
protein
mutat
found
one
four
select
clone
four
five
select
clone
examin
abil
plaquepurifi
virus
grow
select
pressur
neutral
mab
vero
cell
infect
wild
type
escap
mutant
viru
clone
presenc
variou
concentr
respect
mab
use
select
compar
number
plaqu
escap
mutant
wild
type
virus
fig
three
virus
contain
substitut
exhibit
substanti
resist
neutral
effect
even
high
concentr
mgml
escap
mutant
also
sensit
neutral
effect
growth
clone
lack
mutat
protein
inhibit
complet
mgml
indic
escap
mutant
greater
level
resist
mab
shown
clone
two
aa
substitut
compar
clone
singl
aa
modif
clone
result
indic
aa
domain
may
play
major
role
neutral
mab
domain
substitut
identifi
one
clone
clone
rel
resist
concentr
approxim
mgml
compar
wild
type
viru
fig
although
subclon
weakli
resist
much
lower
concentr
approxim
mgml
detect
mutat
region
clone
neutral
curv
shown
fig
indic
concentr
use
mgml
suffici
select
escap
mutant
mutat
altern
possibl
low
affin
antibodi
requir
mani
molecul
exert
clear
neutral
effect
assay
three
clone
contain
substitut
thu
substitut
occur
rbd
region
appear
import
viral
escap
neutral
effect
addit
aa
alter
identifi
appear
give
advantag
clone
escap
power
neutral
effect
approxim
mgml
thu
doubl
substitut
may
provid
addit
effect
resist
case
clone
analyz
resist
repres
subclon
mab
use
select
fig
expect
grow
well
presenc
left
panel
grow
presenc
middl
right
contrast
similarli
resist
right
resist
middl
similar
growth
affect
minimum
concentr
therefor
contribut
individu
combin
aa
chang
obviou
compar
clear
differ
subclon
result
indic
substitut
aa
play
import
role
neutral
aa
within
major
epitop
taken
togeth
find
indic
stronger
resist
neutral
confer
substitut
critic
residu
domain
next
examin
effect
select
use
combin
two
anti
mab
wild
type
viru
incub
singl
mab
mixtur
mgml
mgml
mgml
fig
repres
lowest
concentr
use
follow
b
c
c
concentr
mab
neutral
viru
half
maximum
condit
combin
two
mab
dramat
inhibit
viral
growth
fig
combin
two
mab
recogn
region
quit
effect
neutral
indic
least
two
type
neutral
antibodi
ie
target
domain
use
effect
passiv
immunotherapi
sar
previous
gener
anti
mab
mice
immun
uvinactiv
viru
studi
character
three
mab
possess
strong
neutral
activ
differ
affin
toward
protein
immunofluoresc
assay
indic
mab
react
similarli
cytoplasm
ergolgi
membran
sarscovinfect
vero
cell
recogn
purifi
virion
blot
onto
membran
flow
cytometri
analysi
suggest
three
mab
recogn
distinct
conform
epitop
protein
furthermor
competit
assay
use
mab
indic
epitop
recogn
overlap
gener
neutral
escap
viral
mutant
mab
detect
substitut
posit
domain
well
domain
indic
major
antigen
determin
includ
aa
domain
wherea
includ
aa
rbd
specul
may
block
viru
entri
interf
interact
rbd
receptor
although
bind
outsid
rbd
low
affin
also
inhibit
viru
entri
presum
interf
conform
chang
region
induc
bind
crystal
structur
rbd
bound
reveal
loop
term
receptorbind
motif
rbm
aa
interact
major
antigen
epitop
identifi
thu
far
shown
local
region
exampl
yi
et
al
identifi
posit
charg
region
aa
within
protein
critic
induct
neutral
antibodi
dna
immun
mice
found
pseudovirus
contain
substitut
fail
induc
neutral
mab
indic
substitut
identifi
reflect
virolog
import
region
interestingli
well
conserv
sarscov
isol
human
relat
virus
civet
palm
civet
cat
bat
whether
neutral
mab
recogn
sarscovrel
isol
bat
need
studi
hypothes
upon
bind
rbd
interact
would
lead
conform
chang
result
membran
fusion
viral
entri
fact
neutral
epitop
local
region
ntermin
region
aa
note
neutral
titer
murin
mab
recogn
aa
rang
approxim
mgml
similar
level
observ
although
substitut
respect
correspond
residu
domain
data
consist
other
suggest
critic
determin
neutral
present
also
region
high
titer
neutral
igg
antibodi
found
sar
patient
accumul
evid
indic
neutral
antibodi
critic
protect
sarscov
infect
thu
passiv
immun
neutral
antibodi
could
effect
sar
therapi
human
mab
develop
use
varieti
techniqu
similar
find
murin
mab
mani
epitop
locat
rbd
review
context
coughlin
et
al
immun
xenomous
mous
immunoglobulin
gene
replac
human
gene
baculovirusderiv
protein
produc
variou
human
mab
neutral
activ
twentyseven
react
varieti
epitop
within
domain
wherea
addit
mab
three
mab
react
domain
exhibit
neutral
activ
importantli
recent
develop
human
neutral
mab
potent
crossreact
mani
clinic
isol
includ
zoonot
virus
previou
studi
escap
mutat
human
neutral
mab
shown
bind
recombin
fragment
aa
singl
substitut
found
isol
virus
recent
rockx
et
al
extens
character
human
mab
identifi
least
six
distinct
neutral
profil
protein
respect
specif
variou
human
zoonot
isol
author
identifi
sever
escap
mutant
virus
broadspectrum
mab
surprisingli
escap
variant
singl
amino
acid
substitut
singl
escap
variant
one
mab
substitut
two
escap
variant
mutat
mab
combin
mab
recogn
distinct
epitop
work
synergist
report
consist
result
demonstr
combin
mab
strongli
neutral
sarscov
much
lower
concentr
requir
neutral
use
singl
mab
viru
contain
substitut
region
exhibit
growth
advantag
wild
type
viru
presenc
effici
neutral
recogn
epitop
thu
predict
treatment
combin
mab
target
could
larg
reduc
risk
escap
mutant
grow
combin
human
neutral
antibodi
effect
treatment
potenti
reemerg
sar
